How Many Adults with Private Health Insurance Could Use GLP-1 Drugs

A KFF analysis reveals that 42% or 57.4 million adults under 65 with private insurance could qualify for GLP-1 drugs used to treat diabetes and obesity. Despite the low prescription rate in 2022, demand and spending on these drugs is growing, prompting employers and insurers to impose stricter eligibility standards due to high costs.